TABLE 2.
Demographic, clinical and therapeutic data of patients who present “troublesome dyskinesia” at T1 vs. patients who had no “troublesome dyskinesia” at T1
| Troublesome dyskinesia at T1 (n = 17) | No troublesome dyskinesia at T1 (n = 36) | P values patients with “troublesome dyskinesia” vs. patients without “troublesome dyskinesia” | |||
| Clinical features | |||||
| Age (yr) | |||||
| at T0 | 68.5 ± 4.5 | 66.8 ± 7.5 | 0.8 | ||
| at T1 | 72.2 ± 8.1 | 71.2 ± 8.1 | |||
| Women: n (%) | 14 (82%) | 6 (16%) | <0.001 | ||
| Age at disease onset (yr) | 55.2 ± 6.4 | 51.8 ± 8.1 | 0.1 | ||
| Disease duration (yr) | |||||
| at T0 | 13.7 ± 4.3 | 15.2 ± 5.5 | 0.5 | ||
| at T1 | 17.5 ± 6.7 | 19.4 ± 6.8 | |||
| Duodopa therapy duration (mo) | 46.6 ± 27.7 | 53.6 ± 37.7 | 0.1 | ||
| Clinical Phenotype n (%) | AK = 10 (58) | AK = 19 (52) | 0.3 | ||
| TD = 4 (24) | TD = 15 (43) | ||||
| Mixed = 3 (18) | Mixed = 2 (5) | ||||
| Baseline vs. follow‐up comparisons | T0 | T1 | T0 | T1 | |
| LEDD (l‐dopa), mg | 1170 ± 633 | 1373 ± 419 a | 1131 ± 472 | 1538 ± 405 a | 0.8 at T0 and 0.16 at T1 |
| Total LEDD, mg | 1333 ± 633 | 1406 ± 402 | 1408 ± 380 | 1515 ± 415 | 0.6 |
| Total LEDD/kg (mg/kg) | 21.4 ± 11.1 | 26.2 ± 8.7 a | 19.5 ± 5.1 | 23.1 ± 6.4 a | 0.1 |
| Amantadine (a = no; b = yes; c = stopped because of AEs; d = stopped because of inefficacy) | NA | b = 3; c = 9; d = 5 | NA | a = 34; b = 2; | |
| H&Y | 2.9 ± 1.1 | 3.1 ± 1.1 | 2.6 ± 0.9 | 3.1 ± 0.9 a | 0.8 |
| SE | 62.2 ± 19.1 | 53.3 ± 13.2 a | 61.2 ± 23.1 | 53.1 ± 26.5 a | 0.9 |
| MDS.UPDRS II (Med On) | 16.2 ± 4.7 | 24.4 ± 11.3 a | 18.2 ± 9.1 | 28.1 ± 12.6 a | 0.2 |
| MDS.UPDRS III Med Off | 53.3 ± 12.4 | NA | 57.2 ± 13.8 | NA | 0.5 |
| MDS.UPDRS III Med On | 30.8 ± 20.3 | 45.3 ± 13.5 a | 35.1 ± 14.1 | 47.6 ± 19.4 a | b = 0.4 |
| UPDRS IV, Total score | 10.4 ± 2.4 | 7.8 ± 2.2 a | 8.6 ± 3.1 | 3.1 ± 1.9 a | 0.06 (T0) and <0.001 (T1) |
| MMSE | 26.7 ± 7.5 | 25.3 ± 3.3 a | 26.1 ± 6.6 | 21.1 ± 9.2 a | 0.9 (T0) and 0.053 (T1) |
| Weight (kg) | 63.4 ± 13.3 | 56.8 ± 12.2 a | 73.3 ± 13.8 a | 68.7 ± 12.1 | 0.015 (T0) and 0.001 (T1) |
| WL (kg) – n (%) | / | 6.4 ± 9.8–14 (82) | / | 4.3 ± 8.5–17 (47) | 0.3 |
| BMI (kg/m2) | 24.3 ± 4.3 | 22.3 ± 3.2 a | 26.2 ± 4.1 | 24.1 ± 4.3 a | 0.008 (T0) and 0.006 (T1) |
Values are presented as mean ± standard deviation (SD) if not otherwise specified.
a
P value <0.05 comparing T0 versus T1 within each group of patients. Statistical significant results are in bold.
SE, Schwab and England ADL scale; H&Y, Hoehn Yahr stage; LEDD, l‐dopa equivalent daily dose; MMSE, mini mental state examination; BMI, body mass index; WL, weight loss; /: not performed.